

Carlo Torti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1259922/publications.pdf>

Version: 2024-02-01

178
papers

5,270
citations

117571

34
h-index

106281

65
g-index

182
all docs

182
docs citations

182
times ranked

7633
citing authors

#	ARTICLE	IF	CITATIONS
1	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 803.	1.8	8
2	Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience. <i>BMC Infectious Diseases</i> , 2022, 22, 113.	1.3	6
3	Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105253.	1.0	5
4	Role of IgG and IgM and proinflammatory aspecific markers in the diagnosis and prognosis of COVID-19 patients stratified by number of positive SARS-CoV-2 genes. <i>Minerva Medica</i> , 2022, , .	0.3	0
5	Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital. <i>Microbial Drug Resistance</i> , 2022, 28, 425-435.	0.9	10
6	Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2279.	1.0	13
7	Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice. <i>World Journal of Gastroenterology</i> , 2022, 28, 1226-1238.	1.4	3
8	Is the Pendulum of Antimicrobial Drug Resistance Swinging Back after COVID-19?. <i>Microorganisms</i> , 2022, 10, 957.	1.6	12
9	Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets. <i>Diagnostics</i> , 2022, 12, 1364.	1.3	5
10	Weight of Clinical and Social Determinants of Metabolic Syndrome in People Living with HIV. <i>Viruses</i> , 2022, 14, 1339.	1.5	7
11	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. <i>Biomedicines</i> , 2022, 10, 1548.	1.4	2
12	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	2.9	8
13	Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. <i>Journal of Medical Virology</i> , 2021, 93, 32-34.	2.5	37
14	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	1.8	87
15	Therapy with RAS inhibitors during the COVID-19 pandemic. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 329-334.	0.6	5
16	Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. <i>Journal of Translational Medicine</i> , 2021, 19, 79.	1.8	24
17	What Every Reader Should Know About Studies Using Electronic Health Record Data but May Be Afraid to Ask. <i>Journal of Medical Internet Research</i> , 2021, 23, e22219.	2.1	61
18	Characteristics, Management, and Outcomes of Elderly Patients with Diabetes in a Covid-19 Unit: Lessons Learned from a Pilot Study. <i>Medicina (Lithuania)</i> , 2021, 57, 341.	0.8	4

#	ARTICLE	IF	CITATIONS
19	A case report of pneumomediastinum in a COVID-19 patient treated with high-flow nasal cannula and review of the literature: Is this a spontaneous complication?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04007.	0.2	5
20	Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1655.	1.0	3
21	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.4	2
22	Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level. <i>Health Science Reports</i> , 2021, 4, e273.	0.6	2
23	Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 613-614.	0.7	1
24	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. <i>JAMA Network Open</i> , 2021, 4, e2112596.	2.8	33
25	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	1.2	8
26	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.1	2
27	Efficacy and durability of two vs. three drug integrase inhibitor based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	1.0	18
28	Histopathology and immunophenotyping of late onset cutaneous manifestations of COVID-19 in elderly patients: Three case reports. <i>World Journal of Clinical Cases</i> , 2021, 9, 5744-5751.	0.3	3
29	Analysis of the persistence time of the SARS-CoV-2 virus in the cadaver and the risk of passing infection to autopsy staff. <i>Medico-Legal Journal</i> , 2021, 89, 40-53.	0.2	11
30	A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines. <i>Pathogens</i> , 2021, 10, 1364.	1.2	19
31	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. <i>Scientific Reports</i> , 2021, 11, 20238.	1.6	10
32	Multidisciplinary approach to a septic COVID-19 patient undergoing venovenous extracorporeal membrane oxygenation and receiving thoracic surgery. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04828.	0.2	0
33	Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. <i>Medicine (United States)</i> , 2021, 100, e27418.	0.4	0
34	Changing epidemiology of hepatitis C in Italy: a population-based survey in a historically high endemic area. <i>Minerva Medica</i> , 2021, , .	0.3	0
35	Has COVID-19 changed the approach to HIV diagnosis?. <i>Medicine (United States)</i> , 2021, 100, e27418.	0.4	7
36	Outcome of HBV screening and vaccination in a migrant population in southern Italy. <i>Infezioni in Medicina</i> , 2021, 29, 236-241.	0.7	0

#	ARTICLE	IF	CITATIONS
37	598â€ŒAre risk scores sufficient to stratify patients undergoing lead extraction? A single-centre analysis. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
38	Molecular characterization of <i>Schistosoma</i> infections in African migrants: identification of a <i>Schistosoma haematobium-bovis</i> hybrid in bladder biopsies. <i>Journal of Travel Medicine</i> , 2021, , .	1.4	0
39	Use of colistin in adult patients: A cross-sectional study. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 43-49.	0.9	29
40	Ceftolozane/tazobactam for difficult-to-treat <i>Pseudomonas aeruginosa</i> infections: A systematic review of its efficacy and safety for off-label indications. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105891.	1.1	33
41	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	1.3	7
42	Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096301.	1.0	18
43	Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101826.	1.5	4
44	Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. <i>Scientific Reports</i> , 2020, 10, 20834.	1.6	65
45	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	1.1	137
46	Spontaneous and severe haematomas in patients with COVID-19 on low-molecular-weight heparin for paroxysmal atrial fibrillation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020054.	0.5	9
47	Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 246.	0.4	16
48	Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?. <i>Vaccines</i> , 2020, 8, 227.	2.1	7
49	Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?. <i>BMC Infectious Diseases</i> , 2020, 20, 412.	1.3	12
50	Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). <i>Medicina (Lithuania)</i> , 2020, 56, 101.	0.8	5
51	Histopathological findings in a COVID-19 patient affected by ischemic gangrenous cholecystitis. <i>World Journal of Emergency Surgery</i> , 2020, 15, 43.	2.1	51
52	Identification of pmrB mutations as putative mechanism for colistin resistance in <i>A. baumannii</i> strains isolated after in vivo colistin exposure. <i>Microbial Pathogenesis</i> , 2020, 142, 104058.	1.3	10
53	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infectionâ€ŒResults of Italian Network of ACuTe HIV Infection (IN ACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16
54	HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018). <i>Open Microbiology Journal</i> , 2020, 14, 84-90.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Evidence of Low Prevalence of Cystic Echinococcosis in the Catanzaro Province, Calabria Region, Italy. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1951-1954.	0.6	8
56	Risk factors for hepatitis B and C among healthy population: a community-based survey from four districts of Southern Italy. <i>Infezioni in Medicina</i> , 2020, 28, 223-226.	0.7	2
57	Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?. <i>Infezioni in Medicina</i> , 2020, 28, 258-262.	0.7	3
58	Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR <i>Acinetobacter baumannii</i> and KPC-producing <i>Klebsiella pneumoniae</i> : a case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3399-3401.	1.3	54
59	Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series. <i>BMC Infectious Diseases</i> , 2019, 19, 858.	1.3	4
60	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1224-1228.	1.0	15
61	Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. <i>Cells</i> , 2019, 8, 416.	1.8	6
62	Ecology of Italian Protura. <i>Pedobiologia</i> , 2019, 73, 20-28.	0.5	6
63	Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2336-2340.	0.2	6
64	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. <i>Aids</i> , 2019, 33, 315-326.	1.0	4
65	Identification of human papillomavirus type 16 variants circulating in the Calabria region by sequencing and phylogenetic analysis of HPV16 from cervical smears. <i>Infection, Genetics and Evolution</i> , 2019, 68, 185-193.	1.0	10
66	Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 30-36.	4.5	17
67	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	2.9	105
68	Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. <i>Journal of Medical Virology</i> , 2018, 90, 1257-1263.	2.5	9
69	Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 6-8.	0.9	12
70	Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. <i>BMC Infectious Diseases</i> , 2018, 18, 518.	1.3	12
71	Increase of Vascular Endothelial Growth Factor and Decrease of MCP-1 and Some Updated Epidemiology Aspects of Cystic Echinococcosis Human Cases in Calabria Region. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	1.4	15
72	Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 230-234.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Direct-Acting Antiviral Naïve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity. <i>ChemistrySelect</i> , 2018, 3, 6009-6017.	0.7	7
74	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2186-2196.	1.3	4
75	Utility of Molecular Identification and Quantitation of Bartonella Species with Species-Specific Real-Time PCR for Monitoring Treatment Response: A Case Series. <i>Open Microbiology Journal</i> , 2018, 12, 148-153.	0.2	3
76	Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 151-162.	4.5	13
77	Prevalence of parasitic infections in migrants: do official symptom-driven guidelines apply to the current situation?. <i>Infezioni in Medicina</i> , 2018, 26, 347-355.	0.7	2
78	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	0.9	15
79	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
80	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
81	Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. <i>BMC Evolutionary Biology</i> , 2017, 17, 70.	3.2	21
82	Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. <i>BMC Infectious Diseases</i> , 2017, 17, 212.	1.3	0
83	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	1.3	17
84	Knowledge of Human Cytomegalovirus Infection and Prevention in Pregnant Women: A Baseline, Operational Survey. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2017, 2017, 1-5.	0.4	10
85	Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 249-259.	4.5	20
86	Patterns of multi-drug resistant bacteria at first culture from patients admitted to a third level University hospital in Calabria from 2011 to 2014: implications for empirical therapy and infection control. <i>Infezioni in Medicina</i> , 2017, 25, 98-107.	0.7	9
87	Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1416.	1.8	14
88	Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. <i>PLoS ONE</i> , 2016, 11, e0162320.	1.1	16
89	Epstein-Barr and cytomegalovirus DNA salivary shedding correlate with long-term plasma HIV RNA detection in HIV-infected men who have sex with men. <i>Journal of Medical Virology</i> , 2016, 88, 1211-1221.	2.5	8
90	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 268-280.	2.9	13

#	ARTICLE	IF	CITATIONS
91	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
92	The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. <i>BMC Public Health</i> , 2016, 16, 878.	1.2	37
93	A case report of <i>Schistosoma haematobium</i> infection in a pregnant migrant raises concerns about lack of screening policies. <i>Journal of Travel Medicine</i> , 2016, 24, taw076.	1.4	5
94	Liver fibrosis progression and clinical outcomes are intertwined. <i>Medicine (United States)</i> , 2016, 95, e4091.	0.4	17
95	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2928-2937.	1.3	7
96	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
97	Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine ATV/r in Patients with Preserved Renal Function. <i>Open AIDS Journal</i> , 2016, 10, 136-143.	0.1	5
98	Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?. <i>World Journal of Hepatology</i> , 2016, 8, 815.	0.8	6
99	The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?. <i>Hepatitis Monthly</i> , 2016, 16, e41933.	0.1	11
100	Is hand-grip another culprit for the risk of fractures in HIV-positive patients?. <i>New Microbiologica</i> , 2016, 39, 61-4.	0.1	3
101	Knowledge of HIV infection and transmission: a knowledge, attitudes, beliefs and practices (KABP) survey among a sample of students at the "Magna Graecia", University of Catanzaro. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2016, 52, 530-535.	0.2	4
102	Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200/mm ³ Despite Effective HAART. <i>PLoS ONE</i> , 2015, 10, e0124741.	1.1	36
103	Virological Mechanisms in the Coinfection between HIV and HCV. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	1.4	21
104	The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. <i>Journal of Nephrology</i> , 2015, 28, 393-402.	0.9	15
105	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015, 29, 193-200.	1.0	13
106	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv043.	0.4	30
107	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	3.9	70
108	Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. <i>World Journal of Hepatology</i> , 2015, 7, 44.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications. <i>Infezioni in Medicina</i> , 2015, 23, 224-9.	0.7	18
110	Update on different aspects of HCV variability: focus on NS5B polymerase. <i>BMC Infectious Diseases</i> , 2014, 14, S1.	1.3	25
111	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. <i>PLoS Pathogens</i> , 2014, 10, e1004345.	2.1	76
112	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3085-3094.	1.3	6
113	Update on epidemiology of HCV in Italy: focus on the Calabria Region. <i>BMC Infectious Diseases</i> , 2014, 14, S2.	1.3	40
114	Back to the origin of HCV 2c subtype and spreading to the Calabria region (Southern Italy) over the last two centuries: A phylogenetic study. <i>Infection, Genetics and Evolution</i> , 2014, 26, 352-358.	1.0	21
115	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
116	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. <i>Infection, Genetics and Evolution</i> , 2013, 19, 349-360.	1.0	4
117	Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. <i>Lancet, The</i> , 2013, 381, 735-743.	6.3	455
118	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	2.9	56
119	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	3.9	256
120	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	2.9	92
121	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. <i>PLoS ONE</i> , 2013, 8, e61436.	1.1	17
122	All-cause mortality in treated HIV-infected adults with CD4 ≥ 500 /mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	0.9	217
123	The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naïve to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 637-640.	0.5	0
124	Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. <i>HIV Clinical Trials</i> , 2012, 13, 245-255.	2.0	24
125	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 119-127.	4.6	41
126	Unboosted Atazanavir for Treatment of HIV Infection. <i>Drugs</i> , 2012, 72, 1161-1173.	4.9	16

#	ARTICLE	IF	CITATIONS
127	High prevalence of radiological vertebral fractures in HIV-infected males. <i>Endocrine</i> , 2012, 41, 512-517.	1.1	52
128	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , 2011, 11, 363-371.	4.6	345
129	Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules. <i>Current HIV Research</i> , 2011, 9, 61-69.	0.2	3
130	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 1164-1173.	2.9	70
131	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2372-2378.	1.3	30
132	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	1.3	56
133	Predicting the magnitude of short-term CD4 ⁺ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	0.6	16
134	Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time. <i>PLoS ONE</i> , 2010, 5, e11505.	1.1	56
135	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	1.1	94
136	Increasing Clinical Virulence in Two Decades of the Italian HIV Epidemic. <i>PLoS Pathogens</i> , 2009, 5, e1000454.	2.1	33
137	A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. <i>Artificial Intelligence in Medicine</i> , 2009, 47, 63-74.	3.8	55
138	Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis. <i>Journal of Medical Virology</i> , 2008, 80, 747-753.	2.5	17
139	A king in the CASTLE? Optimum initial HIV protease inhibitor. <i>Lancet</i> , 2008, 372, 604-606.	6.3	2
140	Plasma HIV Load and Proviral DNA Decreases After Two Standard Antiretroviral Regimens in HIV-Positive Patients Naïve to Antiretrovirals. <i>Current HIV Research</i> , 2008, 6, 43-48.	0.2	13
141	Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 757-758.	1.8	191
142	Risk of Early Virological Failure of Once-Daily Tenofovir-Emtricitabine plus Twice-Daily Nevirapine in Antiretroviral Therapy-Naïve HIV-1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2008, 46, 1127-1129.	2.9	39
143	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	1.0	188
144	Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV. <i>Antiviral Therapy</i> , 2008, 13, 341-348.	0.6	13

#	ARTICLE	IF	CITATIONS
145	Prevalence and Risk Factors for Etravirine Resistance among Patients Failing on Non-Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2008, 13, 601-605.	0.6	26
146	CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1141-1147.	1.3	4
147	Predictors of AIDS-Defining Events Among Advanced Naïve Patients After HAART. <i>HIV Clinical Trials</i> , 2007, 8, 112-120.	2.0	22
148	Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide. <i>Aids</i> , 2007, 21, 1388-1389.	1.0	5
149	Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens. <i>Drug Safety</i> , 2007, 30, 1161-1169.	1.4	21
150	Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 185-190.	1.1	10
151	Predictors of Clinical Progression among HIV-1 Positive Patients starting HAART with CD4 ⁺ T-cell Counts ≥ 200 cells/mm ³ . <i>Antiviral Therapy</i> , 2007, 12, 941-948.	0.6	15
152	Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. <i>Antiviral Therapy</i> , 2007, 12, 1175-1184.	0.6	22
153	Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors. <i>Journal of Clinical Virology</i> , 2006, 35, 414-419.	1.6	11
154	Natural history of chronic hepatitis B in co-infected patients. <i>Journal of Hepatology</i> , 2006, 44, S65-S70.	1.8	198
155	Comparison of a Rule-Based Algorithm with a Phenotype-Based Algorithm for the Interpretation of HIV Genotypes in Guiding Salvage Regimens in HIV-Infected Patients by a Randomized Clinical Trial: The Mutations and Salvage Study. <i>Clinical Infectious Diseases</i> , 2006, 42, 1470-1480.	2.9	11
156	Influence of Folate Serum Concentration on Plasma Homocysteine Levels in HIV-Positive Patients Exposed to Protease Inhibitors Undergoing HAART. <i>Annals of Nutrition and Metabolism</i> , 2006, 50, 247-252.	1.0	17
157	Influence of Hepatitis C Genotypes on Lipid Levels in HIV-Positive Patients during Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 521-527.	0.6	12
158	The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens. <i>Antiviral Therapy</i> , 2006, 11, 923-930.	0.6	7
159	Genotyping for Guiding Drug Choice in Human Immunodeficiency Virus-Infected Children Failing Multiple Antiretroviral Treatment Regimens. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 747-749.	1.1	8
160	A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study. <i>Clinical Infectious Diseases</i> , 2005, 40, 1828-1836.	2.9	49
161	Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naïve HIV-positive patients: results from the Italian MASTER Cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 190-195.	1.3	35
162	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005, 7, 161-7.	0.5	3

#	ARTICLE	IF	CITATIONS
163	Early Virological Failure after Tenofovir + Didanosine + Efavirenz Combination in HIV-Positive Patients upon Starting Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2005, 10, 505-513.	0.6	21
164	Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. <i>Intervirology</i> , 2004, 47, 350-354.	1.2	3
165	Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 29-33.	2.5	6
166	Immune Correlates of Virological Response in HIV-Positive Patients after Highly Active Antiretroviral Therapy (HAART). <i>Viral Immunology</i> , 2004, 17, 279-286.	0.6	17
167	Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection. <i>Antiviral Therapy</i> , 2004, 9, 139-142.	0.6	13
168	Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. <i>Health Policy</i> , 2003, 65, 261-267.	1.4	18
169	Comparison between Rules-Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients. <i>Journal of Infectious Diseases</i> , 2003, 188, 194-201.	1.9	53
170	SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1079-1082.	0.5	7
171	HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 776-781.	1.3	4
172	Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 141-143.	1.0	33
173	Effect of Highly Active Antiretroviral Therapy (HAART) and Hepatitis C Co-Infection on Hyperlipidemia in HIV-Infected Patients: A Retrospective Longitudinal Study. <i>HIV Clinical Trials</i> , 2002, 3, 451-461.	2.0	27
174	Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. <i>Journal of Clinical Laboratory Analysis</i> , 2002, 16, 76-78.	0.9	7
175	No evidence of beneficial effect of GB virus type C infection on the course of HIV infection. <i>Aids</i> , 2002, 16, 1430-1431.	1.0	21
176	Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. <i>Journal of Clinical Laboratory Analysis</i> , 2001, 15, 43-46.	0.9	20
177	Prevalence and distribution of soil-transmitted helminth (STH) infections in urban and indigenous schoolchildren in Ortigueira, State of Parana, Brasil: implications for control. <i>Tropical Medicine and International Health</i> , 2000, 5, 302-307.	1.0	50
178	Naive CD4+T Lymphocytes Express High Levels of Bcl-2 after Highly Active Antiretroviral Therapy for HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1805-1807.	0.5	13